7/2/2010

The FDA granted orphan-drug designation to sapacitabine, Cyclacel Pharmaceuticals' experimental drug for acute myeloid leukemia and bone marrow stem cell disorder. The drugmaker plans to proceed with pivotal late-stage trials of the product this year.

Full Story:
Reuters

Related Summaries